Protocol Ledger

NCT03678545 · Phase II · COMPLETED

Dupilumab in Eosinophilic Gastritis

Interventional Phase II clinical trial protocol NCT03678545 sponsored by Children's Hospital Medical Center, Cincinnati in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-15 Enrollment: 41 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03678545
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)41 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03678545
Protocol FieldVerified Registry Value
NCT IdentifierNCT03678545
Consolidated Lead SponsorChildren's Hospital Medical Center, Cincinnati
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment41 participants (ACTUAL)
Registered Start Date2021-05-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Cincinnati Children's Hospital Medical Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI